Kisspeptin-10
- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
In 2003, two independent research teams — Seminara at Harvard and de Roux in Paris — published in the same month a finding that rewrote reproductive endocrinology textbooks. People with loss-of-function mutations in a gene called GPR54 fail to enter puberty. The receptor's natural ligand turned out to be kisspeptin, encoded by the KISS1 gene. Suddenly the entire reproductive cascade had a master upstream regulator nobody knew existed before.
What Is Kisspeptin-10?
Kisspeptin-10 (KP-10) is a synthetic 10-amino-acid peptide — the minimal bioactive C-terminal fragment of the natural KISS1 gene product. Native kisspeptin exists in several lengths (kisspeptin-54, -14, -13, and -10), but the final 10 residues retain full agonist activity at the GPR54 receptor (also called KISS1R). The shorter sequence makes KP-10 the most synthetically accessible and most-used kisspeptin variant in research.
What makes the compound mechanistically remarkable: kisspeptin sits one step upstream of GnRH in the hypothalamic-pituitary-gonadal axis. Kisspeptin neurons in the arcuate nucleus and anteroventral periventricular area release kisspeptin onto GnRH neurons. GnRH then drives LH and FSH release from the pituitary. LH and FSH drive gonadal steroid production. Activate kisspeptin signaling, and the entire cascade fires. Block it, and reproductive function shuts down.
The Discovery That Changed Reproductive Biology
The KISS1 gene was originally identified as a metastasis suppressor in melanoma research — hence the unusual name (the "KI" prefix acknowledges Hershey, Pennsylvania where it was discovered, the "SS" stands for suppressor sequence, and "Kisses" refers to the famous Hershey's chocolates). Nobody connected it to reproduction until those 2003 papers showed that GPR54 mutations cause hypogonadotropic hypogonadism. The same gene that suppresses cancer metastasis also turns out to be the master regulator of fertility.
Multiple human clinical trials have followed. KP-10 has been tested in idiopathic hypogonadotropic hypogonadism, IVF triggering protocols, hypothalamic amenorrhea, and sexual desire disorders. The 2017 Imperial College trial and subsequent work demonstrated KP-10's ability to stimulate LH release in human subjects and showed effects on brain regions involved in sexual processing — the latter finding generated significant research interest in kisspeptin's potential role beyond pure reproductive endocrinology.
What Serious Buyers Should Know
Here's the uncomfortable truth: chronic kisspeptin administration causes tachyphylaxis — the response diminishes rapidly with repeated dosing. Continuous KP-10 exposure desensitizes the GPR54 receptor and can actually suppress gonadotropin output rather than stimulate it. Some studies of repeated kisspeptin-54 injections over two weeks reported reduced LH/FSH and sex steroid levels. That paradoxical effect is biologically interesting (it's potentially useful in hormone-dependent cancer research) but it makes KP-10 a difficult tool for sustained reproductive axis stimulation. Pulsatile dosing matters here in ways that don't apply to most other peptides.
The plasma half-life of KP-10 is short — approximately 4 minutes intravenously, longer with subcutaneous administration — which is why most published research uses continuous infusion or carefully timed pulse protocols rather than single bolus dosing. That short half-life is one reason the KP-54 variant has competed with KP-10 in some clinical trial work.
Regulatory note: Kisspeptin-10 was reviewed by the FDA's Pharmacy Compounding Advisory Committee on October 29, 2024, alongside Ipamorelin and Ibutamoren. The FDA's pre-meeting analysis recommended against 503A Bulks List inclusion, and the PCAC voted accordingly. As of May 2026, Kisspeptin-10 is not on the Category 1 bulks list and cannot be compounded by 503A pharmacies. It also was not part of the recent April 2026 reclassification activity affecting BPC-157, Epitalon, DSIP, and others. Sales as a research compound continue legally. WADA prohibits kisspeptin and analogs for athletes in tested sports.
Why Generic Peptides for Kisspeptin-10?
Here's a sourcing problem that's specific to Kisspeptin-10: it's an amidated peptide at the C-terminus, and the C-terminal amide is essential for GPR54 receptor binding. Cheap synthesis routinely produces material with a free carboxyl group instead of the amide — and that single difference dramatically reduces receptor affinity. The peptide arrives looking right on a label, with the right molecular weight within tolerance, but doesn't bind GPR54 the way the literature describes. Without HPLC-MS verification specifically checking for C-terminal amidation, this defect is invisible to buyers and ruins the experiment.
Generic Peptides supplies research-grade Kisspeptin-10 for sale at 99% purity, manufactured in the USA. Domestic synthesis with verified C-terminal amidation — the part that determines whether your KP-10 actually behaves like KP-10 in receptor binding studies.
Order Kisspeptin-10 for sale in the USA — 99% purity, C-terminal amide verified, manufactured domestically.
Kisspeptin-10 FAQ
Is it legal to buy Kisspeptin-10 in the US for research?
Yes — Kisspeptin-10 is legally available as a research compound in the United States. It was reviewed by the PCAC on October 29, 2024, which voted against Category 1 bulks list inclusion. It cannot currently be compounded by 503A pharmacies. Sales as a research compound continue legally. Not FDA-approved for human use.
What's the difference between Kisspeptin-10 and Kisspeptin-54?
KP-10 is the minimal bioactive 10-amino-acid C-terminal fragment; KP-54 is the longer 54-amino-acid form (sometimes called metastin). Both bind GPR54 with similar potency. KP-10 is smaller, easier to synthesize, and more affordable. KP-54 has a significantly longer half-life. Researchers choose between them based on protocol requirements.
Why does Kisspeptin-10 have such a short half-life?
The 10-amino-acid peptide is rapidly cleaved by peptidases in plasma — approximately 4 minutes intravenously, longer subcutaneously. That short duration is actually an advantage in some research designs (controlled, time-limited GnRH activation) but a limitation in others. Some research protocols use continuous infusion to maintain steady-state exposure rather than bolus dosing.
Does Kisspeptin-10 actually trigger LH release in humans?
Yes — that's the most reliably reproduced finding in human kisspeptin research. KP-10 administration triggers measurable LH release in healthy subjects, in patients with hypothalamic amenorrhea, and in idiopathic hypogonadotropic hypogonadism studies. The magnitude varies by dose, route, and patient population, but the LH response is a robust pharmacological signature of kisspeptin activity.
I've seen Kisspeptin-10 sold for half this price elsewhere — same product?
Probably not. The C-terminal amide modification is essential for GPR54 receptor binding, and cheap synthesis routinely delivers material with a free acid group instead. The peptide looks correct on a label but has dramatically reduced bioactivity. Without HPLC-MS verification of C-terminal amidation, the defect is invisible until your binding assay produces nothing.
Sources
Seminara SB et al. — "The GPR54 gene as a regulator of puberty." New England Journal of Medicine, 2003. Foundational discovery linking GPR54 mutations to hypogonadotropic hypogonadism. https://pubmed.ncbi.nlm.nih.gov/14573733/
de Roux N et al. — "Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54." PNAS, 2003. Independent confirmation of the GPR54-puberty connection. https://pubmed.ncbi.nlm.nih.gov/14523145/
Oakley AE, Clifton DK, Steiner RA — "Kisspeptin signaling in the brain." Endocrine Reviews, 2009. Comprehensive review of kisspeptin's HPG axis regulation. https://pubmed.ncbi.nlm.nih.gov/19549826/
FDA — "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A," PCAC review October 29, 2024 documentation. Documents Kisspeptin-10 review and negative recommendation. https://www.fda.gov/media/185412/download
10 amino acids. One C-terminal amide that determines receptor binding. Sourcing matters at this scale.
Kisspeptin-10 Dosage Guide
Kisspeptin-10 (also called metastin) is a 10-amino-acid neuropeptide that acts upstream of the reproductive axis by binding the GPR54/KISS1R receptor on hypothalamic GnRH neurons, triggering pulsatile GnRH release and downstream LH, FSH, and sex hormone secretion. This guide is aimed at men seeking a physiological alternative to hCG for testicular preservation on TRT, women undergoing IVF or with functional hypothalamic amenorrhea, and users exploring libido and reproductive-axis support. Dosing below combines the Imperial College London clinical research (George et al., Dhillo et al.), the Phase I–II human trials establishing 0.3–10 nmol/kg IV dose-response curves, and community subcutaneous protocols that have emerged for TRT-adjunct use.
Real-World Dosage Protocols by Experience Level
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 50 mcg | Every 3 days, SC | Assess tolerance; monitor LH/FSH/testosterone |
| Standard (men) | 100 mcg | 2–3 times weekly, SC | Most common TRT-adjunct community protocol |
| Intermediate | 200 mcg | 2–3 times weekly, SC | Upper end of HPG support range |
| Pre-activity (libido) | 100–200 mcg | 30–60 min before activity, SC | Single-dose acute use |
| Clinical research (IV bolus) | 0.3–1 mcg/kg | Single dose, IV | Peak LH response; 1 mcg/kg is saturation |
| Clinical infusion | 1.5–4 mcg/kg/h | Continuous IV | Research setting only; sustains LH pulse frequency |
Doses also shift depending on the specific goal. The same peptide used for TRT-adjunct testicular support versus female IVF ovulation triggering can follow quite different protocols.
Dosage by Goal
| Goal | Recommended Dose | Frequency | Cycle Length |
|---|---|---|---|
| TRT adjunct / testicular preservation | 100 mcg | 2–3 times weekly, SC | Ongoing with TRT |
| Testosterone support (non-TRT) | 100–200 mcg | Every other day, SC | 4–8 weeks, reassess with labs |
| Libido / acute sexual function | 100–200 mcg | Single dose, 30–60 min pre-activity, SC | As needed |
| Post-cycle therapy after AAS | 100 mcg | Every other day, SC | 4–6 weeks alongside SERM |
| Female functional hypothalamic amenorrhea | 100 mcg | 2–3 times weekly, SC | Under medical supervision |
| Female IVF trigger (Kisspeptin-54 clinical) | 6.4 mcg/kg single bolus | One-time trigger | Single dose; clinical setting only |
Avoid daily or continuous dosing — the 2011 JCEM dose-response data shows 3 mcg/kg bolus produced a weaker LH response than 1 mcg/kg, and continuous high-dose infusion obscures the pulsatile pattern that makes Kisspeptin physiologically superior to hCG. Do not combine Kisspeptin-10 with GnRH antagonists (Cetrorelix, Ganirelix), as they directly block the downstream receptor Kisspeptin activates, and using Kisspeptin alongside exogenous testosterone without TRT context defeats its purpose since high testosterone suppresses the GnRH pulse Kisspeptin is trying to stimulate. Monitor LH, FSH, and testosterone or estradiol at baseline and every 4–6 weeks, and avoid in anyone with hormone-sensitive cancers, pregnancy, or uncontrolled reproductive pathology.
Kisspeptin-10 Storage Guide: How to Keep Your Research Peptide Stable and Effective
Kisspeptin-10 ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its 10-amino-acid structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — Kisspeptin-10 contains a tryptophan residue that's particularly prone to photodegradation. | Always keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Oxidation Sensitivity | The tryptophan residue also makes Kisspeptin-10 susceptible to oxidation if the vial seal is broken or the powder is exposed to air. | Keep the aluminum crimp cap intact until ready to reconstitute. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a humid kitchen or bathroom, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 4–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 13–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
Based on 1 reviews
5.0
Using it as part of a post-cycle hormone recovery protocol. The upstream LH stimulation is what sets Kisspeptin apart from everything else — working at the hypothalamic level rather than just patching things downstream. Recovery felt more complete than previous PCTs. Supplier quality is the best I've found for this compound. Second order already placed.
KP-10 binds GPR54 (KISS1R) on hypothalamic GnRH neurons, activating Gq/11-coupled signaling that drives calcium mobilization, ERK1/2 phosphorylation, and p38 MAPK activation. The downstream effect is GnRH release from hypothalamic neurons, which then triggers LH and FSH release from pituitary gonadotropes. The mechanism operates one step upstream of GnRH, making KP-10 an unusually high-leverage tool for studying the entire HPG axis.
Kisspeptin-10 acts upstream of GnRH — it stimulates GnRH-producing neurons rather than mimicking GnRH itself. GnRH analogs (like Gonadorelin) act directly at the pituitary to trigger LH/FSH release. Kisspeptin's mechanism preserves the natural pulsatile pattern of GnRH release, which is why it became interesting for fertility research where GnRH analogs sometimes produce different downstream effects than the natural cascade.
The original KISS1 gene was discovered as a metastasis suppressor in cancer research before its reproductive function was identified. The longer 54-amino-acid form was originally named metastin for its anti-metastatic activity. KP-10 is the bioactive C-terminal fragment of metastin/kisspeptin-54. Same molecular family, different research literatures depending on which application is being studied.
The C-terminal amide modification is essential for GPR54 receptor binding affinity. Cheap synthesis frequently produces material with a free carboxyl group instead of the amide, which dramatically reduces receptor binding. The peptide looks structurally correct on basic analytical methods but doesn't function pharmacologically. HPLC-MS specifically checking C-terminal amidation is required to verify proper synthesis.
The KISS1 gene was discovered in 1996 as a metastasis suppressor. The reproductive function was established in 2003 by the Seminara and de Roux papers showing GPR54 mutations cause hypogonadotropic hypogonadism. KP-10 entered active research as the most synthetically accessible bioactive fragment, with hundreds of preclinical and multiple clinical trials following over the next two decades.
Athletes subject to drug testing should consult their governing body's specific rules. WADA's Prohibited List includes substances that affect the HPG axis, and kisspeptin-related compounds may fall under broader categories targeting hormones and growth factors. The compound's mechanism — directly stimulating LH and testosterone release — places it in a regulatory category of concern for anti-doping authorities.
KP-10, Kisspeptin (110-119) (the position numbering within the larger kisspeptin precursor), Metastin (45-54), and various commercial designations. CAS 374675-21-5. The amino acid sequence YNWNSFGLRF-NH2 with its C-terminal amide identifies the compound unambiguously.
Reproductive endocrinology and HPG axis pharmacology lead by volume — fertility research, IVF triggering protocols, hypogonadotropic hypogonadism models, and pubertal development studies. There's also active work in sexual function research (KP-10 has shown effects on brain regions involved in sexual processing), oncology research from the original metastasis suppressor angle, and emerging research in metabolic/energy balance regulation.
Different compounds at different points in the HPG cascade. Gonadorelin is synthetic GnRH itself, acting directly at the pituitary. Kisspeptin-10 acts upstream at the hypothalamus, stimulating GnRH neurons to release their own GnRH. Gonadorelin is FDA-approved (LutrePulse, generic versions); Kisspeptin-10 is research-only. The mechanisms produce overlapping but not identical pharmacological profiles.
Most reproductive research peptides act at or below the pituitary level — GnRH analogs at the pituitary, gonadotropins at the gonads, sex steroids at peripheral tissues. Kisspeptin-10 is unique in acting one step above GnRH, at the hypothalamic level where reproductive signaling is initially integrated. That upstream position makes it a more fundamental research tool for understanding how the entire reproductive axis is controlled.
Researchers investigating hypothalamic reproductive regulation, GnRH pulse generation, and HPG axis biology consistently examine Kisspeptin-10 alongside compounds that target overlapping or complementary reproductive and neuroendocrine pathways. HCG and HMG are the most natural downstream pairings — Kisspeptin-10 sits upstream of the entire HPG axis activating GnRH release, while HCG and HMG are the gonadotropins that GnRH drives; researchers studying the full regulatory cascade from hypothalamic pulse generation to gonadal response typically examine all three to map which regulatory level drives a given phenotype. PT-141 (Bremelanotide) addresses a related but distinct aspect of reproductive biology — central melanocortin signaling affecting sexual desire rather than HPG axis hormone production — and researchers studying neuroendocrine regulation of sexual function sometimes examine both compounds when the research design requires distinguishing hormonal from neurogenic components. Semax occasionally appears in the same research context given its ACTH-derived mechanism and documented effects on hypothalamic signaling pathways that intersect with GnRH regulation. Each represents a different regulatory level of the hypothalamic-pituitary-gonadal biology that Kisspeptin-10 research addresses.
